Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaceuticalindustries

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy, Sell, Hold: 3 stocks, 1 sector are on investors’ radar on March 6, 2018

      Cyient, Sun Pharma and Tata Motors, among others, are being tracked by analysts on Tuesday.

    • Buy Blue Star, Sun Pharma, LIC Housing Finance: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying Blue Star, Sun Pharma and LIC Housing Finance.

    • Buy Sun Pharma, says Rajat Bose

      Rajat Bose of rajatkbose.com advises buying Sun Pharma.

    • Prefer Sun Pharma, says Vijay Chopra

      Vijay Chopra of enochventures.com is of the view that one may prefer Sun Pharma.

    • Remain neutral on Sun Pharma; many other issues like Taro results persist: Analyst

      Sun Pharma has received 3 observations from US FDA in a re-inspection. In an interview with CNBC-TV18, Amey Chalke, Research Analyst at HDFC Securities shared his views and readings on the same.

    • Buy Persistent Systems, Sun Pharma, Adani Ports, Bajaj Finance, JSPL, NIIT Technologies: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com suggests buying Persistent Systems, Sun Pharma, Adani Ports, Bajaj Finance, JSPL and NIIT Technologies.

    • Sell Motherson Sumi, Bajaj Finance, HDFC, Sun Pharma, Reliance Capital, PC Jeweller: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends selling Motherson Sumi, Bajaj Finance, HDFC, Sun Pharma, Reliance Capital and PC Jeweller.

    • These 7 stocks' fundamentals remained robust despite capex doubling over last 5 fiscals

      These companies, doubled their assets without much leverage and were able to maintain a double-digit sales and profit CAGR.

    • Analysts expect Sun Pharma to fall up to 25% post Q3 earnings, await Halol resolution

      All brokerage houses barring Motilal Oswal highlighted in this article are having Reduce to Hold rating and expect the stock to fall up to 25 percent.

    • Hold Sun Pharma, says Vijay Chopra

      Vijay Chopra of enochventures.com is of the view that one may hold Sun Pharma.

    • Stay invested in Sun Pharma: Rajat Bose

      According to Rajat Bose of rajatkbose.com, one may stay invested in Sun Pharma.

    • Buy Tata Steel, Vedanta, Jindal Steel & Power: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying Tata Steel, Vedanta and Jindal Steel & Power.

    • Sell Tata Chemicals, Pidilite Industries: Mitessh Thakkar

      Mitessh Thakkar of miteshthacker.com suggests selling Tata Chemicals and Pidilite Industries.

    • Sell NTPC, Bharti Infratel; buy Tata Steel, Sun TV, Sun Pharmaceutical Industries: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can sell NTPC and Bharti Infratel and can buy Tata Steel, Sun TV and Sun Pharmaceutical Industries.

    • Buy Sun Pharmaceutical Industries, RBL Bank, CG Power, Ceat, KPIT Technologies, Britannia Industries: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying Sun Pharmaceutical Industries, RBL Bank and CG Power.

    • Buy ICICI Prudential Life Insurance, Sun Pharmaceutical Industries: Prakash Gaba

      Prakash Gaba of prakashgaba.com is of the view that one can buy ICICI Prudential Life Insurance and Sun Pharmaceutical Industries.

    • Buy KPIT Technologies, Siemens; hold Sun Pharma, Vakrangee: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy KPIT Technologies and Siemens and can hold Sun Pharma and Vakrangee.

    • Buy Yes Bank, Tata Elxsi, Sun Pharma; sell Mahanagar Gas, Berger Paints: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Yes Bank, Tata Elxsi and Sun Pharmaceutical Industries and can sell Mahanagar Gas and Berger Paints.

    • Buy Sun Pharmaceutical Industries, TCS, UltraTech Cement, Bajaj Finance: VK Sharma

      VK Sharma, Head - PCG and Capital Market Strategy at HDFC Securities is of the view that one can buy Sun Pharmaceutical Industries, TCS, UltraTech Cement and Bajaj Finance.

    • Sell PNB, HPCL; buy Hexaware, Infosys, Jubilant Foodworks, Sun Pharma: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can sell PNB and HPCL and can buy Hexaware, Infosys, Jubilant Foodworks and Sun Pharma.

    • Buy TCS; sell IFCI, Canara Bank: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one may buy Tata Consultancy Services.

    • Buy Tata Elxsi, Sun Pharma, Ajanta Pharma: Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that one may buy Tata Elxsi, Sun Pharma and Ajanta Pharma.

    • Buy, Sell, Hold: 6 stocks and 2 sectors on analysts radar on January 10

      Morgan Stanley feels APA with US Internal Revenue Service could positively impact FY19/20 EPS by up to 1 percent. The research house has Equalweight rating on the stock with target at Rs 1,028 per share.

    • Buy Sun Pharmaceutical Industries, Manappuram Finance, Mahindra & Mahindra: Rahul Shah

      Rahul Shah, Associate VP at Motilal Oswal suggests buying Sun Pharmaceutical Industries, Manappuram Finance and Mahindra & Mahindra.

    • Buy Federal Bank 115 Call, RBL Bank 550 Call, Sun Pharma 660 Call: VK Sharma

      VK Sharma, Head - PCG and Capital Market Strategy at HDFC Securities is of the view that one can buy Federal Bank 115 Call, RBL Bank 550 Call and Sun Pharmaceutical Industries 660 Call.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347